Analyzing Perspective Therapeutics (NYSE:CATX) and Stevanato Group (NYSE:STVN)
by Doug Wharley · The Cerbat GemPerspective Therapeutics (NYSE:CATX – Get Free Report) and Stevanato Group (NYSE:STVN – Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, analyst recommendations and risk.
Profitability
This table compares Perspective Therapeutics and Stevanato Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Perspective Therapeutics | N/A | -32.87% | -28.06% |
| Stevanato Group | 11.27% | 10.89% | 6.33% |
Insider and Institutional Ownership
54.7% of Perspective Therapeutics shares are held by institutional investors. 3.5% of Perspective Therapeutics shares are held by company insiders. Comparatively, 0.7% of Stevanato Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Volatility and Risk
Perspective Therapeutics has a beta of 1.43, indicating that its share price is 43% more volatile than the S&P 500. Comparatively, Stevanato Group has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Perspective Therapeutics and Stevanato Group, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Perspective Therapeutics | 0 | 0 | 8 | 1 | 3.11 |
| Stevanato Group | 0 | 2 | 3 | 0 | 2.60 |
Perspective Therapeutics presently has a consensus target price of $21.43, indicating a potential upside of 68.07%. Given Perspective Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Perspective Therapeutics is more favorable than Stevanato Group.
Valuation & Earnings
This table compares Perspective Therapeutics and Stevanato Group”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Perspective Therapeutics | $1.43 million | 555.14 | -$46.51 million | N/A | N/A |
| Stevanato Group | $1.17 billion | N/A | $157.62 million | €0.50 ($0.54) | 36.40 |
Stevanato Group has higher revenue and earnings than Perspective Therapeutics.
Summary
Perspective Therapeutics beats Stevanato Group on 7 of the 12 factors compared between the two stocks.
About Perspective Therapeutics
Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.
About Stevanato Group
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.